Dexamethasone as a probe for vinorelbine clearance |
| |
| Authors: | Puisset Florent Dalenc Florence Chatelut Etienne Cresteil Thierry Lochon Isabelle Tisnes Pierre Roché Henri |
| |
| Affiliation: | EA3035, Institut Claudius-Regaud, Toulouse, France. |
| |
| Abstract: | AIM: To assess the value of using dexamethasone as an in vivo probe for predicting vinorelbine clearance (CL). METHODS: A population approach (implemented with NONMEM) was used to analyse blood vinorelbine pharmacokinetic data from 20 patients who received a 20-min intravenous infusion of vinorelbine (from 20 to 30 mg m(-2)). Selected patient clinical data as well as known functional single CYP3A5 and ABCB1 genotype were also tested as covariates. RESULTS: The best covariate model (with +/- 95% confidence intervals) was based on dexamethasone plasma clearance (DPC) and alkaline phosphatase (ALP): vinorelbine blood CL (l h(-1)) = 39.8(+/- 4.0) x (DPC/13.2)(0.524(+/-0.322)) x (ALP/137)(-0.198(+/-0.158)). Interindividual variability in vinorelbine CL decreased from 29.7% (model without covariate) to 14.7% when including DPC and ALP. Vinorelbine CL was not correlated with body surface area (BSA) or associated with CYP3A5 and ABCB1 genotype. CONCLUSIONS: These results indicate that individualization of vinorelbine dose would be improved by using dexamethasone clearance rather than BSA. Dexamethasone merits further evaluation as a probe of CYP3A metabolism. |
| |
| Keywords: | cytochrome P450 3A4/ 5 dexamethasone P-glycoprotein population pharmacokinetics vinorelbine |
| 本文献已被 PubMed 等数据库收录！ |
